Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026)
Apogee Therapeutics (APGE) reported Income from Continuing Operations of 74111000.0 for Q1 2026, down 33.92% year-over-year from 112156551.78 in Q1 2025, and down 6.81% on a QoQ basis from 69387000.0 in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of Income from Continuing Operations data on file, last reported at 74111000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 33.92% year-over-year to 74111000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 274615000.0 (down 33.7% YoY) and the FY2025 annual result came in at 255843000.0, down 40.46% from the prior year.
- Income from Continuing Operations retreated to 74111000.0 in Q1 2026 per APGE's latest filing, from 69387000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 43631000.0 in Q4 2023 and bottomed at 74111000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 32955000.0 (2024), against an average of 34196312.5.
- Peak annual rise in Income from Continuing Operations reached 409.46% in 2023, while the deepest fall reached 939.92% in 2023.
- Tracing APGE's Income from Continuing Operations over 5 years: stood at 14099000.0 in 2022, then jumped by 409.46% to 43631000.0 in 2023, then sank by 254.06% to 67218000.0 in 2024, then fell by 3.23% to 69387000.0 in 2025, then dropped by 6.81% to 74111000.0 in 2026.
- Per Business Quant, the three latest APGE Income from Continuing Operations figures stand at 74111000.0 (Q1 2026), 69387000.0 (Q4 2025), and 65021000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -74.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -69.39 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -67.22 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | 43.63 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.10 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |